Last updated on March 2018

A clinical trial to evaluate treatments for patients with Acute Coronary Syndrome

Brief description of study

The purpose of this study is to determine if Apixaban is safer than a Vitamin K Antagonist given for 6 months in terms of bleeding in patients with an irregular heart beat (atrial fibrillation) and a recent heart attack or a recent procedure to open up a blood vessel in the heart. All patients would also be taking a class of medicines called P2Y12 inhibitors (such as clopidogrel/Plavix) and be treated for up to 6 months. The primary focus will be a comparison of the bleeding risk of Apixaban, with or without aspirin, versus a Vitamin K antagonist, such as warfarin, with or without aspirin.

Detailed Study Description

Patients will be recruited from either inpatient coronary care or general medical units, or recruited from outpatient cardiology offices.


Apixaban: Open label.

VKA: Open label.

Acetylsalicylic acid film coated tablet: Double Blinded.

Placebo matching Acetylsalicylic acid film coated tablet: Double Blinded.

Clinical Study Identifier: NCT02415400

Contact Investigators or Research Sites near you

Start Over

Recruiting sites have contact information. ...

Local Institution
Katy, TX United States
  Connect »